In vivo antitumor efficacy of interleukin-21 in combination with chemotherapeutics

Cytokine

Volumn 48, Issue 3, 2009, Pages 231-238

  Skak, Kresten ^a   Søndergaard, Henrik ^a   Frederiksen, Klaus Stensgaard ^a   Ehrnrooth, Eva ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Chemotherapy; Cytokines; Immunotherapy; In vivo models

Indexed keywords

ANTIMETABOLITE; CYTOKINE; CYTOSTATIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; FLUOROURACIL; GRANZYME B; INTERLEUKIN 21; IRINOTECAN; MESSENGER RNA; OXALIPLATIN; PLATINUM DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; IMMUNOPATHOLOGY; IN VIVO STUDY; KIDNEY CARCINOMA; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; LYMPHOCYTOSIS; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TUMOR MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; FEMALE; FLUOROURACIL; INTERLEUKINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; T-LYMPHOCYTES;

MUS;

EID: 70350129921     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.07.039     Document Type: Article

References (30)

1. Parrish-Novak J., Dillon S.R., Nelson A., Hammond A., Sprecher C., Gross J.A., et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408 (2000) 57-63
2. Coquet J.M., Kyparissoudis K., Pellicci D.G., Besra G., Berzins S.P., Smyth M.J., et al. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol 178 (2007) 2827-2834
3. Asao H., Okuyama C., Kumaki S., Ishii N., Tsuchiya S., Foster D., et al. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 167 (2001) 1-5
4. Strengell M., Sareneva T., Foster D., Julkunen I., and Matikainen S. IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. J Immunol 169 (2002) 3600-3605
5. Brenne A., Ro T.B., Waage A., Sundan A., Borset M., and Hjorth-Hansen H. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 99 (2002) 3756-3762
6. Spolski R., and Leonard W.J. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 26 (2008) 57-79
7. + T cells and inhibits the growth of syngeneic tumors. Cancer Immunol Immunother 56 (2007) 1417-1428
8. + T cell expansion and function. J Exp Med 201 (2005) 139-148
9. Brady J., Hayakawa Y., Smyth M.J., and Nutt S.L. IL-21 induces the functional maturation of murine NK cells. J Immunol 172 (2004) 2048-2058
10. Wang G., Tschoi M., Spolski R., Lou Y., Ozaki K., Feng C., et al. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 63 (2003) 9016-9022
11. + T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol 173 (2004) 900-909
12. Davis I.D., Skrumsager B.K., Cebon J., Nicholaou T., Barlow J.W., Moller N.P.H., et al. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res 13 (2007) 3630-3636
13. Thompson J.A., Curti B.D., Redman B.G., Bhatia S., Weber J.S., Agarwala S.S., et al. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 26 (2008) 2034-2039
14. Davis I.D., Brady B., Kefford R.F., Millward M., Cebon J., Skrumsager B.K., et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res 15 (2009) 2123-2129
15. Lake R.A., and Robinson B.W. Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 5 (2005) 397-405
16. Fujii S., Shimizu K., Smith C., Bonifaz L., and Steinman R.M. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 198 (2003) 267-279
17. Giaccone G., Punt C.J., Ando Y., Ruijter R., Nishi N., Peters M., et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8 (2002) 3702-3709
18. Zitvogel L., Apetoh L., Ghiringhelli F., and Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8 (2008) 59-73
19. Kasaian M.T., Whitters M.J., Carter L.L., Lowe L.D., Jussif J.M., Deng B.J., et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16 (2002) 559-569
20. King C., Ilic A., Koelsch K., and Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 117 (2004) 265-277
21. Frederiksen K.S., Lundsgaard D., Freeman J.A., Hughes S.D., Holm T.L., Skrumsager B.K., et al. IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother 57 (2008) 1439-1449
22. Lake R.A., and van der Most R.G. A better way for a cancer cell to die. N Engl J Med 354 (2006) 2503-2504
23. Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.L., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13 (2007) 54-61
24. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13 (2007) 1050-1059
25. Ewens A., Luo L., Berleth E., Alderfer J., Wollman R., Hafeez B.B., et al. Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice. Cancer Res 66 (2006) 5419-5426
26. Coukos G., Conejo-Garcia J.R., Roden R.B.S., and Wu T.C. Immunotherapy for gynaecological malignancies. Expert Opin Biol Ther 5 (2005) 1193-1210
27. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348 (2003) 203-213
28. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58 (1998) 3491-3494
29. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006) 1960-1964
30. + T cell infiltrations within esophageal carcinomas. Cancer Res 61 (2001) 3932-3936